% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Antonini:258252,
author = {Antonini, Angelo and Reichmann, Heinz and Gentile, Giovanni
and Garon, Michela and Tedesco, Chiara and Frank, Anika and
Falkenburger, Bjoern and Konitsiotis, Spyridon and Tsamis,
Konstantinos and Rigas, Georgios and Kostikis, Nicholas and
Ntanis, Adamantios and Pattichis, Constantinos},
title = {{T}oward objective monitoring of {P}arkinson's disease
motor symptoms using a wearable device: wearability and
performance evaluation of {PDM}onitor®.},
journal = {Frontiers in neurology},
volume = {14},
issn = {1664-2295},
address = {Lausanne},
publisher = {Frontiers Research Foundation},
reportid = {DZNE-2023-00598},
pages = {1080752},
year = {2023},
abstract = {Parkinson's disease (PD) is characterized by a variety of
motor and non-motor symptoms. As disease progresses,
fluctuations in the response to levodopa treatment may
develop, along with emergence of freezing of gait (FoG) and
levodopa induced dyskinesia (LiD). The optimal management of
the motor symptoms and their complications, depends,
principally, on the consistent detection of their course,
leading to improved treatment decisions. During the last few
years, wearable devices have started to be used in the
clinical practice for monitoring patients' PD-related motor
symptoms, during their daily activities. This work describes
the results of 2 multi-site clinical studies (PDNST001 and
PDNST002) designed to validate the performance and the
wearability of a new wearable monitoring device, the
PDMonitor®, in the detection of PD-related motor symptoms.
For the studies, 65 patients with Parkinson's disease and 28
healthy individuals (controls) were recruited. Specifically,
during the Phase I of the first study, participants used the
monitoring device for 2-6 h in a clinic while neurologists
assessed the exhibited parkinsonian symptoms every half hour
using the Unified Parkinson's Disease Rating Scale (UPDRS)
Part III, as well as the Abnormal Involuntary Movement Scale
(AIMS) for dyskinesia severity assessment. The goal of Phase
I was data gathering. On the other hand, during the Phase II
of the first study, as well as during the second study
(PDNST002), day-to-day variability was evaluated, with
patients in the former and with control subjects in the
latter. In both cases, the device was used for a number of
days, with the subjects being unsupervised and free to
perform any kind of daily activities. The monitoring device
produced estimations of the severity of the majority of
PD-related motor symptoms and their fluctuations.
Statistical analysis demonstrated that the accuracy in the
detection of symptoms and the correlation between their
severity and the expert evaluations were high. As a result,
the studies confirmed the effectiveness of the system as a
continuous telemonitoring solution, easy to be used to
facilitate decision-making for the treatment of patients
with Parkinson's disease.},
keywords = {Parkinson's disease (Other) / automatic ambulatory
monitoring (Other) / digital health (Other) / inertial
measurement unit sensors (Other) / telemonitoring (Other) /
wearable devices (Other)},
cin = {AG Kempermann 1 ; AG Kempermann / Clinical Study Team
Dresden ; AG Falkenburger},
ddc = {610},
cid = {I:(DE-2719)1710001 / I:(DE-2719)1710012},
pnm = {352 - Disease Mechanisms (POF4-352) / 353 - Clinical and
Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-352 / G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37260606},
pmc = {pmc:PMC10228366},
doi = {10.3389/fneur.2023.1080752},
url = {https://pub.dzne.de/record/258252},
}